311 related articles for article (PubMed ID: 18571160)
1. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Wu J; Wang Q; Guo J; Hu Z; Yin Z; Xu J; Wu X
Eur J Pharmacol; 2008 Jul; 589(1-3):220-4. PubMed ID: 18571160
[TBL] [Abstract][Full Text] [Related]
2. [Ca2+]i and PKC-alpha are involved in the inhibitory effects of Ib, a novel nonpeptide AngiotensinII subtype AT1 receptor antagonist, on AngiotensinII-induced vascular contraction in vitro.
Wang Y; Wang W; Wang Q; Wu J; Xu J; Wu X
Biochem Biophys Res Commun; 2007 Dec; 364(1):118-23. PubMed ID: 17931598
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist.
Tamura K; Okuhira M; Amano H; Inokuma K; Hirata T; Mikoshiba I; Hashimoto K
J Cardiovasc Pharmacol; 1997 Nov; 30(5):607-15. PubMed ID: 9388043
[TBL] [Abstract][Full Text] [Related]
4. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
Hilditch A; Hunt AA; Travers A; Polley J; Drew GM; Middlemiss D; Judd DB; Ross BC; Robertson MJ
J Pharmacol Exp Ther; 1995 Feb; 272(2):750-7. PubMed ID: 7853190
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.
Edwards RM; Aiyar N; Ohlstein EH; Weidley EF; Griffin E; Ezekiel M; Keenan RM; Ruffolo RR; Weinstock J
J Pharmacol Exp Ther; 1992 Jan; 260(1):175-81. PubMed ID: 1309870
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
De Godoy MA; Rattan S
J Pharmacol Exp Ther; 2006 Aug; 318(2):725-34. PubMed ID: 16648368
[TBL] [Abstract][Full Text] [Related]
8. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.
Chiu AT; McCall DE; Price WA; Wong PC; Carini DJ; Duncia JV; Wexler RR; Yoo SE; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):711-8. PubMed ID: 2313596
[TBL] [Abstract][Full Text] [Related]
9. Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist.
Gao T; Liu Y; Ji Y; Wu X; Xu J
J Pharm Biomed Anal; 2012 Jul; 66():381-6. PubMed ID: 22516679
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Clin Sci (Lond); 2000 Oct; 99(4):331-41. PubMed ID: 10995600
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753.
Wong PC; Timmermans PB
J Pharmacol Exp Ther; 1991 Jul; 258(1):49-57. PubMed ID: 2072311
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, U-97018.
Kushida H; Nomura S; Morita O; Harasawa Y; Suzuki M; Nakano M; Ozawa K; Kunihara M
J Pharmacol Exp Ther; 1995 Sep; 274(3):1042-53. PubMed ID: 7562467
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonist.
Olins GM; Corpus VM; Chen ST; McMahon EG; Palomo MA; McGraw DE; Smits GJ; Null CL; Brown MA; Bittner SE
J Cardiovasc Pharmacol; 1993 Oct; 22(4):617-25. PubMed ID: 7505365
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of KR-30988, a novel non-peptide AT1 receptor antagonist, in rat, rabbit and dog.
Lee BH; Lee SH; Jung YS; Seo HW; Yoo SE; Shin HS
J Pharm Pharmacol; 1999 Oct; 51(10):1191-200. PubMed ID: 10579691
[TBL] [Abstract][Full Text] [Related]
15. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.
Ojima M; Igata H; Tanaka M; Sakamoto H; Kuroita T; Kohara Y; Kubo K; Fuse H; Imura Y; Kusumoto K; Nagaya H
J Pharmacol Exp Ther; 2011 Mar; 336(3):801-8. PubMed ID: 21123673
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
Choi SM; Seo MJ; Kang KK; Kim JH; Ahn BO; Yoo M
Arch Pharm Res; 2009 Mar; 32(3):353-8. PubMed ID: 19387578
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist.
Chi YH; Lee JH; Kim JH; Tan HK; Kim SL; Lee JY; Rim HK; Paik SH; Lee KT
Biol Pharm Bull; 2013; 36(7):1208-15. PubMed ID: 23811571
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism.
Jiménez-Ferrer E; Badillo FH; González-Cortazar M; Tortoriello J; Herrera-Ruiz M
J Ethnopharmacol; 2010 Jul; 130(2):340-6. PubMed ID: 20488233
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis.
Price A; Lockhart JC; Ferrell WR; Gsell W; McLean S; Sturrock RD
Arthritis Rheum; 2007 Feb; 56(2):441-7. PubMed ID: 17265479
[TBL] [Abstract][Full Text] [Related]
20. Properties of [3H]LF 7-0156, a new nonpeptide antagonist radioligand for the type 1 angiotensin II receptor.
Nouet S; Dodey P; Renaut P; Marie J; Pruneau D; Larguier R; Lombard C; Bonnafous JC
Mol Pharmacol; 1994 Oct; 46(4):693-701. PubMed ID: 7969048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
